Sept 29, 2025 3-5pm ET
Monday on The Robert Scott Bell Show:
Hour 1
Trump Posts Video On Medical Benefits Of Cannabis For Seniors As White House Weighs Rescheduling The article reports that former President Trump shared a nearly three-minute video emphasizing the potential medical benefits of hemp-derived CBD for older adults, framing it as a groundbreaking health initiative. The video highlights how CBD may help reduce pain, inflammation, and stress, while also supporting the endocannabinoid system in ways that could slow disease progression and improve quality of life. It suggests that integrating CBD into Medicare and training physicians on its therapeutic uses could extend healthy years for seniors, calling it “the most important senior health initiative of the century.” Although Trump did not add commentary beyond reposting the video, the timing coincides with ongoing White House deliberations about whether to reschedule marijuana under federal law. The article underscores the ambiguity of the message, since the video focuses on CBD rather than whole cannabis, yet its release may influence the broader debate. It also situates the development within larger policy battles in Congress, where some lawmakers have proposed restrictions on hemp products containing even trace amounts of THC. Critics argue such measures would effectively dismantle the CBD market, while Trump’s promotion signals political recognition of the compound’s popularity and potential among senior voters. The piece concludes by noting that the move could further elevate cannabis and hemp policy into the national spotlight at a critical regulatory juncture.
He helped build the anti-vaccine movement. RFK Jr. just hired him. The article reports that Mark Blaxill, a longtime anti-vaccine activist, has been hired by the Centers for Disease Control and Prevention as a senior adviser under Health Secretary Robert F. Kennedy Jr., a move that critics say signals a restructuring of federal vaccine policy along anti-vaccine lines. Blaxill, neither a physician nor a scientist, has for decades promoted the disproven theory that vaccines cause autism, blaming thimerosal and environmental exposures, and serving in leadership roles at groups such as SafeMinds and the website Age of Autism. His claims have been repeatedly rejected by major scientific bodies, including the Institute of Medicine. Despite this, an internal profile shows he will work directly under the CDC chief of staff and may be positioned to influence autism tracking programs. His hiring follows a pattern of appointments of Kennedy allies, including former Children’s Health Defense leaders, anti-vaccine researchers, and congressional staffers, who have already reshaped vaccine advisory committees to scale back recommendations for flu and Covid shots. Critics like Dr. Paul Offit argue that Kennedy is surrounding himself with people who share his belief that vaccines cause autism, while career CDC officials have resigned in protest over being sidelined. Blaxill has a history of accusing the CDC of cover-ups, urging parents not to vaccinate during outbreaks, and publishing disputed research such as the retracted “Autism Tsunami” paper, which exaggerated autism costs and incidence. His addition comes amid heightened attention to autism policy by President Trump, who recently echoed unsubstantiated claims linking autism to vaccines and Tylenol. The article concludes that Blaxill’s appointment raises concerns that disproven vaccine-autism theories may soon shape official CDC reports and recommendations under Kennedy’s leadership.
Obama Defends Tylenol, Gets Wrecked in Replies The article describes how former President Barack Obama entered the growing debate over acetaminophen use in pregnancy by posting on X that “broad claims around certain drugs and autism” have been continuously disproven. He insisted that such claims are misleading, heighten parental anxiety, and cause pregnant women to avoid safe pain relief unnecessarily. Obama’s remarks were met with swift and intense backlash online, where critics argued that his dismissal ignored mounting research suggesting potential risks associated with prenatal Tylenol exposure. Many users accused him of carrying water for pharmaceutical interests rather than acknowledging legitimate scientific concerns. The article notes that Johnson & Johnson, the maker of Tylenol, has maintained that acetaminophen is the safest pain reliever available during pregnancy when used as directed, while recommending that pregnant women consult their doctors before taking any medication. However, the piece emphasizes that dozens of observational studies have raised questions about links between acetaminophen use during pregnancy and later developmental conditions, including autism spectrum disorders and attention-related issues. Though these studies do not establish causation, they have prompted ongoing lawsuits and calls for clearer product warnings, and critics argued that Obama’s statement downplayed these developments. Social media responses described his comments as tone-deaf, accusing him of protecting industry rather than vulnerable mothers and children. The article frames the episode as a public relations miscalculation, presenting Obama as out of step with a growing movement of parents, researchers, and advocates demanding more transparency about potential risks of commonly used medications.
SCOOP: Tylenol Maker Privately Admitted Evidence Was Getting ‘Heavy’ for Autism Risk in 2018 Internal documents released via a class action lawsuit reveal that in 2018, Johnson & Johnson’s epidemiology division expressed concern internally that “the weight of the evidence is starting to feel heavy” regarding links between prenatal acetaminophen (Tylenol) use and neurodevelopmental disorders such as autism. The company monitored scientific publications suggesting consistent associations between in utero exposure and outcomes like autism and hyperkinetic features, and acknowledged weaknesses in those observational studies (such as confounding factors and measurement subjectivity). Emails to company leaders in earlier years show that queries from physicians and consumer reports about possible links had prompted internal safety reviews. Johnson & Johnson also conducted “social listening” to track public sentiment on Tylenol and autism, and in a 2023 internal review recognized that acknowledging plausible risks “touches every aspect of the brand.” Publicly, the company maintains there is no causal link and asserts acetaminophen is safe when used according to label instructions, though court filings show the company considered but ultimately did not fund follow-up studies due to fear of confirming the associations. The internal documents contrast sharply with Johnson & Johnson’s external stance, revealing that concerns about risk were considered internally even while publicly denied.
Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!
On The Robert Scott Bell Show today, we feature Oleum Animale Aethereum—an old homeopathic remedy prepared from animal oil distilled with bone.
Boericke places it among the remedies with strong action on the nervous system, especially where spasms, hysteria, or convulsions are present.
NEED DATA SHEET
Hour 2
RFK Jr. May Add Autism Symptoms to Federal Vaccine Injury Compensation Program A proposal under consideration by Health Secretary Robert F. Kennedy Jr. would expand the list of compensable injuries under the National Vaccine Injury Compensation Program (VICP) to include symptoms often associated with autism, though not autism itself. Vaccine-injury advocate Drew D. Downing described efforts to identify mechanisms by which neurological injuries underlying autistic traits might be captured via broader definitions like encephalopathic events or neurological damage. Proponents argue that this approach would allow families affected by neurodevelopmental disorders to seek redress without having autism explicitly listed. Wayne Rohde—an expert in vaccine compensation—cautioned that while autism is not currently recognized as a vaccine injury, the program has traditionally limited eligibility via a fixed injury table, and expanding it could pressure the system. Kennedy has criticized VICP for its narrow scope and announced goals to make compensation faster and less adversarial, including removing barriers erected over decades. Supporters such as James Lyons-Weiler contend that symptom-based compensation could deliver “economic justice” to families whose children have experienced neurological conditions. However, critics warn that such changes would “radically transform” the VICP, risk overwhelming it given existing backlogs, and potentially erode vaccine confidence by implying causation between vaccines and autism. The proposal emerges amid Kennedy’s broader push to explore vaccine risks and causes of autism, and raises legal, practical, and scientific questions about causation, program capacity, and implications for public health policy.
Special Guest: Dr. Sheila Furey
Dr. Sheila Furey is the President of the Virginia Medical Freedom Alliance, a nonprofit organization of medical professionals and concerned citizens who formed in the midst of covid in order to inform and educate the public about early treatment for Covid 19 and the danger of the Covid shots. This organization has expanded to address medical freedom from conception to natural death and stands on the foundation of the Hippocratic Oath and the Constitution to protect patient autonomy and “do no harm”. She is a practicing psychiatrist and has recently authored a chapter in the soon to be published book Urban Legends by Christine Dolan exposing the harms of the gender dysphoria.
Question of The Day!
What is the thing we’re supposed to ask to have reinstated – CPG 400 something? Do you have a statement that says it exactly so I can read it off? I’ve tried following what you say & just don’t quite get it.
Thank you so much. I’ve recently discovered you & watch most of your shows on Rumble.
Sue B
ANH Lawsuit Against FDA Homeopathy Guidance Gains Media Attention A recent HBW Insight feature spotlighted the legal fight between ANH-USA (alongside homeopathy company Meditrend) and the FDA over the agency’s 2022 guidance that rescinded its previous Compliance Policy Guide (CPG 400.400) and reclassified homeopathic products as “new drugs” subject to full FDA approval. The court dismissed several of ANH’s claims but upheld one, acknowledging that ANH and Meditrend demonstrated standing by showing economic harm—specifically citing the removal of certain homeopathic products from Whole Foods shelves following the FDA’s policy change. ANH plans to appeal parts of the ruling, arguing that the court erred in treating key facts as undisputed and weighing the merits prematurely. The litigation has drawn media attention as ANH contends that the FDA’s actions have rattled the homeopathic supply chain—manufacturers and suppliers are reportedly less willing to produce homeopathic remedies amid increased regulatory scrutiny, leading to product shortages. The court has ordered the FDA to disclose its full administrative record to justify the policy shift. A final decision may not arrive until mid-2026, but ANH says it is preparing for a sustained fight to protect access to homeopathic products and to prevent what it calls overreach by regulatory agencies.
Remember Friends, The Power to Heal is Yours!
Remember Friends, The Power to Heal is Yours!